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Persistence is the twin sister of excellence. One
is a matter of quality; the other, a matter of time.
Marabel Morgan
C
onsider 2011 as the culminating year for the
decade of clinical trials seeking to alter immune-
mediated destruction of b-cells in type 1 diabetes.
Emphasizing this past decade is not meant to
diminish earlier studies (1), or the seminal trial in 1984
demonstrating the effects of cyclosporine on preservation of
b-cell function (2); indeed it was the sobering results from
the latter study (i.e., better insulin secretion but worsening
renal function) that pushed the ﬁeld to test new approaches
aimed at achieving some sort of tolerance—i.e., a safe,
short-term intervention that would enable a “reset” of the
immune system away from self-destruction and provide
long-term clinical beneﬁts. To achieve such a goal would
not be easy, but would require a remarkable degree of
persistence.
To this end, in 2002 and 2005 reports from two trials
using modiﬁed anti-CD3 antibodies hinted at the promise
for such a new approach (3,4). Since then, early evidence
has been reported that therapies of similar therapeutic
purpose but targeting completely different mechanistic
pathways (e.g., antigen based with GAD65-alum, anti-B
lymphocyte) may have also beneﬁcially altered the disease
course after type 1 diabetes onset (5–8). But 2011 is a key
year not only because results of a number of major clinical
trials will be reported from nonproﬁt- or federally funded
studies, but it represents the year that results will be dis-
closed from studies involving “big pharma,” often in as-
sociation with biotech companies. And it is with this
notion that we will build our case for the importance of
these trial results for all those interested in type 1 diabetes.
Drug development requires collaboration between aca-
demia, regulatory authorities, and pharmaceutical com-
panies. As recently highlighted by the new Center for
Translational Medicine and Therapeutics at the National
Institutes of Health (NIH) (9), putting these pieces to-
gether is the only way science will affect human health in
a meaningful way. Unfortunately, until 2001 big pharma did
not, to a meaningful degree, play in the space of altering
immune destruction of b-cells. What brought them in?
One reason was the strategic planning, intensive nego-
tiating, and persistent lobbying by the Juvenile Diabetes
Research Foundation (JDRF), individual investigators
(both inside and outside of academia), and NIH leadership.
Another key was the acceptance by the Food and Drug
Administration and European Regulatory authorities of
C-peptide as an appropriate end point to regulatory ap-
proval. Third was the push from academic investigators
acting collectively in networks, such as the NIH Immune
Tolerance Network (ITN) and Diabetes TrialNet who,
through collaboration, demonstrated the feasibility of
performing large clinical trials with efﬁciency. Finally,
the notion of “reformulating” drugs pharma designed for
other disorders and seeing their potential application in
settings of type 1 diabetes grew increasingly attractive.
Now that all the required players are at the table and we
have the beneﬁt of a decade of experience working to-
gether, it is sobering to ask whether such engagement will
continue if results of the major clinical trials due to report
in 2011 (Table 1) are negative. Scientiﬁcally, either nega-
tive or positive results help the ﬁeld and stimulate new
questions; but if negative results discourage big pharma,
the ﬁeld of type 1 diabetes will suffer a setback. There are
also implications if the trial results are seen as positive.
For example, a drug showing positive inﬂuences on the
disease may sway interest away from other promising
agents due to fears of competition for limited market
space. From observing drug development in other auto-
immune diseases, it is unlikely that any single study will be
compelling enough from a risk/beneﬁt perspective to fun-
damentally alter clinical care in an immediate fashion; yet
there may be impacts on the design of future studies. Our
advice, and hope, is that careful scrutiny of these trials
together will allow investigators to tackle the complex
clinical and regulatory issues surrounding identiﬁcation of
those individual therapies providing the most beneﬁt and,
subsequently, to identify how to combine approaches to
maximal effect. Regardless of positive or negative out-
comes, the need for the partnership between the afore-
mentioned entities will remain.
This having been said, the implications of these trial
results (Table 1) go far beyond the issue of whether pharma
will continue to support this area. As of this writing, the
United States Congress has agreed to funding for the Spe-
cial Type 1 Diabetes appropriation, thus allowing for con-
tinuation of individually or network-funded clinical trials for
at least a short season. In addition to learning from this
critical decade of trials to plan new studies, we must plan
for the future by training clinical investigators—and re-
warding them with academic promotions and grants for
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EDITORIALcollaborative efforts, including participation in clinical tri-
als. Although this challenge is not unique to type 1 diabetes,
the insufﬁcient supply of diabetologists for both clinical
care and research is of considerable concern. Yet, clinical
trials do not happen without understanding of basic scien-
tiﬁc concepts. We must reject the false dichotomy of basic
or clinical research, supporting one at the exclusive ex-
pense of the other. Both are incredibly important and in-
deed, at the close of 2010, it is remarkable how many
fundamental questions regarding type 1 diabetes remain: Is
it a disease of ﬂares and remissions? Do b-cells regularly
regenerate? Why is there heterogeneity in clinical course?
New tools, technology, and analytic approaches from tal-
ented individuals within and outside the diabetes research
ﬁeld should be developed and applied to human tissues
including blood samples and cadaveric specimens. Clearly,
improved biomarkers are also needed: those that track with
disease, those that track with therapy, and those that track
in response to therapy.
Finally, it is important to consider the impact these
clinical trial results will have on patients and families living
with type 1 diabetes. Like other diseases, only a very tiny
fraction of individuals participate in clinical trials (10). If
a series of negative results are reported during 2011, what
will be the impact on their willingness to participate in new
studies? If there are positive results, how will the research
community collectively address the clinical importance of
the reported outcomes? Individuals with diabetes and their
families are already burdened with the emotional, physi-
cal, and ﬁnancial costs of the disease; investigators must
stay connected, must listen, and must solicit ideas from
those directly dealing with diabetes.
Writing just before 1 January 2011, we plan to ring in this
important year with hopeful anticipation of the results
culminating from this past decade of clinical trials. What-
ever the results, a key challenge is to remain persistent.
We must continue to build on the infrastructure, the
human capital, and the goodwill generated to date in order
to see a means for the prevention and cure of this disease
brought to fruition.
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TABLE 1
A sampling of large clinical trials seeking to reverse type 1
diabetes whose results are due for reporting in 2011
Drug Compound Type of trial
Abatacept CTLA4-Ig Phase II (NIH TrialNet)
Diamyd GAD-alum Phase III (Diaprevent)
Phase III (European)
Phase II (NIH TrialNet)
DiaPep277 HSP peptide Phase III
Prochymal Mesenchymal stem Phase II
Teplizumab Anti-CD3 Phase II/III (Protégé)
Phase II (Protégé encoure)
Phase II (NIH, AbATE)
Otelixizumab Anti-CD3 Phase III (Defend-1)
Note: not every clinical trial for type 1 diabetes that is due to report
study results was indicated for the sake of brevity or because of
study size or lack of public information. HSP, heat shock protein.
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